Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
Saved in:
| Title: | Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results. |
|---|---|
| Authors: | Tanaka Y; First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan., Matsubara T; Department of Orthopedics, Matsubara Mayflower Hospital, Kato, Hyogo, Japan., Atsumi T; Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan., Amano K; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Hidaka, Saitama, Japan., Ishiguro N; Aichi Developmental Disability Center, Kasugai, Aichi, Japan., Sugiyama E; Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan., Yamaoka K; Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan., Combe BG; Rheumatology Department, CHU Montpellier, Montpellier University, Montpellier, France., Kivitz AJ; Altoona Center for Clinical Research, Duncansville, PA, USA., Bae SC; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology Research and Hanyang University Institute of Bioscience and Biotechnology, Seoul, Korea., Keystone EC; Department of Medicine, University of Toronto, Toronto, ON, Canada., Nash P; Griffith University of Queensland, Brisbane, Queensland, Australia., Genovese M; Gilead Sciences Inc., Foster City, CA, USA., Matzkies F; Gilead Sciences Inc., Foster City, CA, USA., Bartok B; Gilead Sciences Inc., Foster City, CA, USA., Pechonkina A; Gilead Sciences Inc., Foster City, CA, USA., Kondo A; Gilead Sciences K.K., Tokyo, Japan., Ye L; Gilead Sciences Inc., Foster City, CA, USA., Gong Q; Gilead Sciences Inc., Foster City, CA, USA., Tasset C; Galapagos NV, Mechelen, Belgium., Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, and Saitama Medical University, Iruma, Saitama, Japan. |
| Source: | Modern rheumatology [Mod Rheumatol] 2023 Jul 04; Vol. 33 (4), pp. 668-679. |
| Publication Type: | Randomized Controlled Trial; Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100959226 Publication Model: Print Cited Medium: Internet ISSN: 1439-7609 (Electronic) Linking ISSN: 14397595 NLM ISO Abbreviation: Mod Rheumatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
